Biora Therapeutics Inc
F:4ZU0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (34.4), the stock would be worth €157.25 (2 983% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.1 | €5.1 |
0%
|
| 3-Year Average | 34.4 | €157.25 |
+2 983%
|
| 5-Year Average | 750.8 | €3 434.56 |
+67 244%
|
| Industry Average | 1.7 | €7.98 |
+57%
|
| Country Average | 2.4 | €11.14 |
+118%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
€994.4k
|
/ |
Oct 2024
$892k
|
= |
|
|
€994.4k
|
/ |
Dec 2024
$999.6k
|
= |
|
|
€994.4k
|
/ |
Dec 2025
$2.6m
|
= |
|
|
€994.4k
|
/ |
Dec 2026
$2.8m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Biora Therapeutics Inc
F:4ZU0
|
994.4k EUR | 1.1 | -0 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
102.9B USD | 0.3 | 59.5 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
70.3B EUR | 0.3 | 13.7 | |
| US |
|
Cigna Corp
NYSE:CI
|
75.1B USD | 0.3 | 12.8 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23B EUR | 1 | 18.4 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.6B EUR | 1.1 | 22.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.7B USD | 1.9 | 20.7 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.3B USD | 1.5 | 24 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 0.5 | 10.9 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
10.9B USD | 11.1 | -26.1 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.3B USD | 0.8 | 13.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Biora Therapeutics Inc
Glance View
Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 124 full-time employees. The company went IPO on 2020-06-19. The company delivers therapeutics in two areas: targeted delivery of therapeutics to the site of disease in the gastrointestinal tract and systemic delivery of biotherapeutics. Its research and development pipeline consists of Drug Delivery System (DDS), PGN-600, PGN-001, Oral Biotherapeutics Delivery System (OBDS), PGN-OB1 and PGN-OB2. PGN-600 is liquid formulation of tofacitinib delivered with the DDS for the treatment of ulcerative colitis. PGN-001 is an orally-delivered variant of adalimumab for the treatment of ulcerative colitis. PGN-OB1 is a combination product of a variant of adalimumab and the OBDS for the treatment of inflammatory conditions. PGN-OB2 is a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type two diabetes. The OBDS platform is designed to enable delivery of liquid drug, reducing the need for reformulation.
